These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 14715870)

  • 1. Polymorphisms in the P450 c17 (17-hydroxylase/17,20-Lyase) and P450 c19 (aromatase) genes: association with serum sex steroid concentrations and bone mineral density in postmenopausal women.
    Somner J; McLellan S; Cheung J; Mak YT; Frost ML; Knapp KM; Wierzbicki AS; Wheeler M; Fogelman I; Ralston SH; Hampson GN
    J Clin Endocrinol Metab; 2004 Jan; 89(1):344-51. PubMed ID: 14715870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of serum sex steroid levels and bone mineral density with CYP17 and CYP19 gene polymorphisms in postmenopausal women in Turkey.
    Yilmaz MB; Pazarbasi A; Guzel AI; Kocaturk-Sel S; Kasap H; Kasap M; Urunsak IF; Basaran S; Alptekin D; Demirhan O
    Genet Mol Res; 2011 Sep; 10(3):1999-2008. PubMed ID: 21948762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age.
    Van Pottelbergh I; Goemaere S; Kaufman JM
    J Clin Endocrinol Metab; 2003 Jul; 88(7):3075-81. PubMed ID: 12843146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms associated with circulating sex hormone levels in postmenopausal women.
    Dunning AM; Dowsett M; Healey CS; Tee L; Luben RN; Folkerd E; Novik KL; Kelemen L; Ogata S; Pharoah PD; Easton DF; Day NE; Ponder BA
    J Natl Cancer Inst; 2004 Jun; 96(12):936-45. PubMed ID: 15199113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A gene-to-gene interaction between aromatase and estrogen receptors influences bone mineral density.
    Riancho JA; Zarrabeitia MT; Valero C; Sañudo C; Mijares V; González-Macías J
    Eur J Endocrinol; 2006 Jul; 155(1):53-9. PubMed ID: 16793950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two single nucleotide polymorphisms in the CYP17 and COMT Genes--relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy. The Danish Osteoporosis Prevention Study.
    Tofteng CL; Abrahamsen B; Jensen JE; Petersen S; Teilmann J; Kindmark A; Vestergaard P; Gram J; Langdahl BL; Mosekilde L
    Calcif Tissue Int; 2004 Aug; 75(2):123-32. PubMed ID: 15129369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adiposity, estradiol, and genetic variants of steroid-metabolizing enzymes as determinants of bone mineral density.
    Zarrabeitia MT; Hernandez JL; Valero C; Zarrabeitia A; Amado JA; Gonzalez-Macias J; Riancho JA
    Eur J Endocrinol; 2007 Jan; 156(1):117-22. PubMed ID: 17218734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A common promotor variant in the cytochrome P450c17alpha (CYP17) gene is associated with bioavailability testosterone levels and bone size in men.
    Zmuda JM; Cauley JA; Kuller LH; Ferrell RE
    J Bone Miner Res; 2001 May; 16(5):911-7. PubMed ID: 11341336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation of aromatase gene polymorphism and hormone replacement therapy to serum estradiol levels, bone mineral density, and fracture risk in early postmenopausal women.
    Salmen T; Heikkinen AM; Mahonen A; Kröger H; Komulainen M; Pallonen H; Saarikoski S; Honkanen R; Mäenpää PH
    Ann Med; 2003; 35(4):282-8. PubMed ID: 12846271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aromatase gene (CYP 19) polymorphisms and endogenous androgen concentrations in a multiracial/multiethnic, multisite study of women at midlife.
    Sowers MR; Wilson AL; Kardia SR; Chu J; Ferrell R
    Am J Med; 2006 Sep; 119(9 Suppl 1):S23-30. PubMed ID: 16949385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A common polymorphism in the 5'-untranslated region of the aromatase gene influences bone mass and fracture risk.
    Zarrabeitia MT; Hernández JL; Valero C; Zarrabeitia AL; García-Unzueta M; Amado JA; González-Macías J; Riancho JA
    Eur J Endocrinol; 2004 May; 150(5):699-704. PubMed ID: 15132727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between polymorphisms in tumor necrosis factor (TNF) and TNF receptor genes and circulating TNF, soluble TNF receptor levels, and bone mineral density in postmenopausal Korean women.
    Kim H; Chun S; Ku SY; Suh CS; Choi YM; Kim JG
    Menopause; 2009; 16(5):1014-20. PubMed ID: 19369902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of endogenous hormone concentrations and bone mineral density measures in pre- and perimenopausal women of four ethnic groups: SWAN.
    Sowers MR; Finkelstein JS; Ettinger B; Bondarenko I; Neer RM; Cauley JA; Sherman S; Greendale GA;
    Osteoporos Int; 2003 Jan; 14(1):44-52. PubMed ID: 12577184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aromatase gene and osteoporosis: relationship of ten polymorphic loci with bone mineral density.
    Riancho JA; Zarrabeitia MT; Valero C; Sañudo C; Hernández JL; Amado JA; Zarrabeitia A; González-Macías J
    Bone; 2005 May; 36(5):917-25. PubMed ID: 15794932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women.
    Tworoger SS; Chubak J; Aiello EJ; Ulrich CM; Atkinson C; Potter JD; Yasui Y; Stapleton PL; Lampe JW; Farin FM; Stanczyk FZ; McTiernan A
    Cancer Epidemiol Biomarkers Prev; 2004 Jan; 13(1):94-101. PubMed ID: 14744739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of anastrozole on hormone levels in postmenopausal women with early breast cancer.
    Kyvernitakis I; Albert US; Kalder M; Winarno AS; Hars O; Hadji P
    Climacteric; 2015 Feb; 18(1):63-8. PubMed ID: 24884402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms in the CYP19 and AR genes--relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy: The Danish Osteoporosis Prevention Study.
    Tofteng CL; Kindmark A; Brändström H; Abrahamsen B; Petersen S; Stiger F; Stilgren LS; Jensen JE; Vestergaard P; Langdahl BL; Mosekilde L;
    Calcif Tissue Int; 2004 Jan; 74(1):25-34. PubMed ID: 14517714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship among VDR (BsmI and FokI), COLIA1, and CTR polymorphisms with bone mass, bone turnover markers, and sex hormones in men.
    Braga V; Sangalli A; Malerba G; Mottes M; Mirandola S; Gatti D; Rossini M; Zamboni M; Adami S
    Calcif Tissue Int; 2002 Jun; 70(6):457-62. PubMed ID: 12016463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obesity as a protective factor for postmenopausal osteoporosis.
    Albala C; Yáñez M; Devoto E; Sostin C; Zeballos L; Santos JL
    Int J Obes Relat Metab Disord; 1996 Nov; 20(11):1027-32. PubMed ID: 8923160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions of interleukin-6 promoter polymorphisms with dietary and lifestyle factors and their association with bone mass in men and women from the Framingham Osteoporosis Study.
    Ferrari SL; Karasik D; Liu J; Karamohamed S; Herbert AG; Cupples LA; Kiel DP
    J Bone Miner Res; 2004 Apr; 19(4):552-9. PubMed ID: 15005841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.